MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

NCT07436221 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-02-27

No results posted yet for this study

Summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.

Conditions

Interventions

DRUG

AK139

AK139 regimen 1- subcutaneous injection.

DRUG

AK139

AK139 regimen 2- subcutaneous injection.

DRUG

AK139

AK139 regimen 3- subcutaneous injection.

DRUG

Placebo

subcutaneous injection.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-12-27
Completion
2027-02-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07436221 on ClinicalTrials.gov